A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Erdheim-Chester disease
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2017 Planned End Date changed from 30 Jun 2019 to 30 Dec 2018.
- 19 Aug 2017 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2018.
- 10 Jun 2017 Biomarkers information updated